Kornimate/medical-research-clean huggingface dataset:
validation of a fetal urine peptidome-based classifier to predict post-natal renal function in posterior urethral valves

Conditions: Posterior Urethral Valves

Summary: validate the use of fetal urine peptidome-analysis and explore amniotic fluid markers for the stratification of fetuses with posterior urethral valve for post-natal renal function.

the antenatal project requires the use of fetal urine as well as post-natal urine, post-natal serum and, possibly, amniotic liquid. we will take an additional tube during the takings collected for routine management of the disease. the analysis of samples will be carried out in toulouse at the institute of metabolic and cardiovascular diseases or with fee-for-service suppliers.

Eligibility criteria:
inclusion criteria: * male singleton fetus with megabladder associated with urinary tract anomalies with or without dysplastic or hyperechogenic parenchyma detected in a first ultrasound; * megabladder confirmed in a second ultrasound; * collection of fetal urine taken during the routine management of the disease for the dosage of ß2-microglobulin; * written informed consent. exclusion criteria: * refusal to participate in the study; * person protected by law.

Keywords: renal function post natal peptidome
comparison of the effect of traditional method and eras protocol in obesity surgery

Conditions: Obesity, Morbid; Bariatric Surgery Candidate; Obesity Adult Onset; Obesity Associated Disorder; Diabetes; Nausea; Ache; Pain, Postoperative; Postoperative Nausea; Postoperative Nausea and Vomiting; Post Procedural Discharge; ERAS; DVT

Summary: this study was conducted to compare the effectiveness of care based on the "accelerated recovery after surgery (eras) protocol" and the traditional method in bariatric surgery and demonstrate the difference the two methods based on evidence.

the population of the study consisted of 700 patients over the age of 18 who underwent bariatric surgery in the obesity surgery clinic of a private hospital in 2022. the sample of the study included 128 patients who were willing to undergo bariatric surgery between april 15-july 31, 2022, were in compliance with the research criteria and were voluntarily over the age of 18, 64 in the control and 64 in the experimental group. 128 patients in the sample were assigned to 2 groups using a computer program that generates random numbers. for the purpose of the research, groups were coded as groups a and b, and two different surgical preparations and surgical procedures were applied to the patients in the group. the effects of two different surgical method preparations and the surgical process on the patient's recovery were compared. in the study, the data were collected with the personal introduction form introducing the characteristics of the patients, the rhodes nausea-vomiting and regurgitation index (wpi), the mcgill pain scale and the postoperative evaluation form created within the scope of the eras accelerated care protocol. permission was obtained for the scales, and the content validity calculation of the postoperative evaluation form was made in line with the evaluations of the field experts consisting of physicians and nurses experienced in the eras rapid care protocol. the data were analyzed in spss package program. while calculating frequency, percentage and standard deviation in the evaluation of the data, comparisons between groups were made with the independent sample t-test, and p≤ 0.05 was taken as the significance value of the findings.

Eligibility criteria:
inclusion criteria: * 18-65 years of age who underwent bariatric surgery * open to communication and collaborative, * patients who volunteered to take part in the study exclusion criteria: * patients with major visual, hearing and speech impairments * patients who want to withdraw from the study at any stage of the study

Keywords: dvt bköi̇ dsö asa bki bpd cvi dmah eras fts iasmen mbt lsg
safeguarding the brain of our smallest children-iiiv (safeboosc-iiiv)

Conditions: Hypoxia; Infant, Newborn, Diseases

Summary: the objective of the safeboosc-iiiv trial is to assess benefits and harms of cerebral oximetry in newborns receiving invasive mechanical ventilation. the hypothesis is that: i. cerebral oximetry added to usual care versus usual care alone in newborns receiving invasive mechanical ventilation will increase the number of hospital-free days within 90 days of randomisation. ii. the intervention will decrease a composite outcome of death or moderate to severe neurodevelopmental disability and/or increase the mean parca-r non-verbal cognitive score at two years of corrected age.

safeboosc-iiiv will be an investigator-initiated, multinational, randomised, pragmatic phase iii clinical trial. the trial will be conducted in two steps. in step one, 1,610 newborns will be randomised, and the outcomes will be assessed 90 days after randomisation. funding has been obtained for step one. if further funding is obtained, we will continue to include newborns until a total of 3,000 newborns are randomised and then follow them up at two years of corrected age (step two).

Eligibility criteria:
inclusion criteria: * gestational age more than or equal to 28+0 * postnatal age less than 28 days * expected to receive invasive mechanical ventilation (intubation) for at least 24 hours, as judged by the physician intending to randomise * parental informed consent unless the centre has chosen to use 'opt-out' or deferred consent as consent method * a cerebral oximeter available so monitoring can be started within six hours after initiation of invasive mechanical ventilation exclusion criteria: * suspicion of or confirmed brain injury or disorder (e.g. severe hypoxic-ischemic encephalopathy, intraventricular haemorrhage grade 3 or 4, cerebral malformation, genetic or metabolic disease) * suspicion or diagnosis of congenital heart malformations likely to require surgery

Keywords: near-infrared spectroscopy randomised clinical trial mechanical ventilation
multicenter study comparing taxotere plus curcumin versus taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant (curtaxel)

Conditions: Prostate Cancer Metastatic Castration Resistant

Summary: multicenter randomized phase ii study, double-blind, comparing taxotere plus curcumin versus taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant. assess time to progression (time to progression) of metastatic disease (from first day of treatment in the trial).


Eligibility criteria:
inclusion criteria: * patient older than 18 years. * performance status ≤ 2 according to the who criteria. * life expectancy\> 3 months. * patient in hormonal blockade based on surgical castration by orchiectomy or pulpectomy, medical or agonist or antagonists of lhrh associated or not with anti-androgens or any other treatment that blocks the fraction of non-gonadal testosterone, resulting in a testosterone \<0.5 ng / ml. * patient with adenocarcinoma of the prostate and histologically proven metastatic castration-resistant stage, defined by: objective progression of at least one measurable tumor target and / or assessable by recist, and / or increase in psa ("rising psa"). * satisfactory biological functions (renal, hepatic and hematologic) * patient who signed the consent for participation before entering the study. * affiliation to a social security scheme (or be the beneficiary of such a plan) under the terms of the law of 9 august 2004. exclusion criteria: * age \<18 years. * performance status\> 2 according to the who criteria. * patient deprived of liberty or under guardianship, patient with (the) condition (s) psychological, family, social or geographic may interfere with the proper conduct of the study. * diagnosis of a second malignancy in the past 5 years, with the exception of a basal cell skin cancer considered cured. * patient with brain metastases at initial assessment. * patient with another pathology deemed incompatible with the inclusion in the protocol. * laboratory tests inadequate. * history of malabsorption syndrome or extensive resection of the upper digestive tract. * uncontrolled intercurrent infection. * pathology autoimmune and / or chronic active inflammation. * peripheral neuropathy grade 2 according to the criteria of the national cancer institute - common terminology criteria for adverse events (nci-ctcae, version 4.0). * history of allergy to polysorbate 80. * treatment with nonsteroidal anti-inflammatory and / or cyclooxygenase-2 dated within three weeks. * concomitant with a drug test or participation in another clinical trial within \<30 days treatment. * regular taking dietary supplements.
impact of midodrine administration on the clinical outcome of septic shock patients

Conditions: Septic Shock

Summary: 1. assess the impact of midodrine administration on weaning of iv vasopressors 2. assess the cost effectiveness of using midodrine in critically ill patients

a prospective randomized controlled clinical trial on total 60 critically ill patients admitted to critical care medicine department with indication to iv vasopressor due to septic shock on admission or during intensive care unit stay and they are randomly assigned to either of 2 groups as follows 1. group 1(n=30):will receive iv vasopressor infusion only 2. group 2(n=30):will receive midodrine in addition to iv vasopressor infusion

Eligibility criteria:
inclusion criteria: 1. adult patients (18-80)years 2. hypotensive (systolic blood pressure\<90mm hg)and require iv vasopressor for more than 24 hours 3. require iv vasopressor at rate \ 24 hours exclusion criteria: 1. severe organic heart disease (ejection fraction \<30 percent due to higher risk of arrythmia) 2. bradycardia (hr\<50 b/m)due to higher likelihood of symptomatic bradycardia 3. chronic kidney disease (serum creatinine \>2mg/dl) as midodrine and its active metabolites are almost completely execreated in urine 4. thyrotoxicosis 5. known allergy to midodrine

Keywords: midodrine septic shock norepinephrine weaning
a study investigating the concentrations of darapladib in blood and the safety of this compound in healthy japanese men

Conditions: Atherosclerosis

Summary: this study is being conducted to provide initial safety, tolerability, pk and pd data that will allow further studies with darapladib in japanese patients


Eligibility criteria:
inclusion criteria: * japanese males, 20-64 years of age, inclusive * body weight \>50kg * body mass index (bmi): 18-28 * subjects must have lived outside of japan no more than 10 years * non-smoker or smokes fewer than 10 cigarettes/day exclusion criteria: * history of asthma, anaphylaxis or anaphylactoid reactions, severe allergic responses * history of sensitivity to heparin or heparin-induced thrombocytopenia * history of alcohol/drug abuse or dependence within 12 months of the study * positive syphilis, hiv antibody, hepatitis b, hepatitis c * history of cholecystectomy or biliary tract disease or history of liver disease * participation in a clinical study within 30 days prior to first dose * subject has been exposed to more than 4 chemical entities within 12 months * positive urine drug and alcohol at screening * subject has any medical history or clinically relevant abnormality that would make the subject ineligible for inclusion due to safety reasons.

Keywords: sb480848, japanese healthy volunteers darapladib,
acupuncture for chronic pelvic pain

Conditions: Acupuncture, Chronic Pelvic Pain, Woman

Summary: the aim of the study is to assess the effects and safety of acupuncture for moderate to severe chronic pelvic pain in women.


Eligibility criteria:
inclusion criteria: * female patients aged between 18 and 50. * chronic pelvic pain (with or without dysmenorrhoea or dyspareunia) of at least 6 months duration. * having not used medications, other than rescue medicine, or therapies for chronic pelvic pain for at least 4 weeks before randomization, and consenting not to use throughout the process of the research. * completing weekly pain diary for at least three week during the four-week run-in period, and at least two of the worst pain scoring ≥4 on the numeric rating scale. * volunteering to participate the trial and signing written informed consent. exclusion criteria: * cyclical chronic pelvic pain, such as only with dysmenorrhea. * endometriosis. * adenomyosis. * complex ovarian cyst. * accessory cyst \>5cm. * uterine fibroids \>5cm. * malignant disease. * anterior sacral neurectomy or uterine sacral nerve ablation before or scheduled in the next 6 month. * irritable bowel syndrome. * symptomatic urinary tract infection. * acute pelvic inflammation. * uncontrolled vaginitis. * lactation period, pregnancy, or fetation planned in the next 6 months. * sever disorders in heart, lung, brain, liver, kidney and hematopoietic system, or obvious psychiatric or cognitive dysfunction. * poor adherence.
the effect of fes on children with spinal cord injury

Conditions: Spinal Cord Injury

Summary: regular exercise is strongly recommended to help maintain a healthy lifestyle. unfortunately, children and young adults with damaged spinal cords may not be able to exercise regularly. however, there is an exercise bike specially designed for persons with damaged spinal cords that enables them to pedal by directly stimulating the muscles in their legs. our study is designed to determine the benefits of exercise for spinal cord injured (sci) patients using this bike.

the inability to walk due to spinal cord dysfunction has profound effects on patients, both physiologically and psychologically. complications associated with walking upright include loss of muscle mass from atrophy, reduction in bone mineral density (osteoporosis), compromised cardiovascular endurance, loss of sense of well-being, etc. functional electrical stimulation (fes) of the lower extremities has been found to reverse many of these complications. we propose to examine the use of fes in children who have suffered from spinal cord injury (sci). we plan to examine the effect of fes bike therapy on bone mineral density and psychological well-being.

Eligibility criteria:
inclusion criteria: * age 4-21 * paralysis/lack of sensation in lower extremities due to spinal cord injury. exclusion criteria: * diseases known to affect bone metabolism * a history of hip or knee dislocation or subluxation * the presence of pressure sores in the areas of treatment * the presence of metallic hardware in the femur * a history of peripheral nerve injury, lower motor neuron disease, or chronic corticosteroid use; or a seizure disorder requiring pharmacological antiepileptic therapy that can affect bone mineral density. * individuals with pacemaker devices or unhealed fractures also were excluded.

Keywords: pediatric spinal cord injury fes cycling bone mineral density quality of life
study of rule-based algorithms in anemia management in prevalent hemodialysis patients and its relation to patients' outcomes

Conditions: Anemia in End Stage Renal Disease

Summary: the study will assess role of rule based algorithm in anemia management in hemodialysis patients and its relation to patient's mortality


Eligibility criteria:
inclusion criteria: * patients on hemodialysis for more than six months patients undergoing hemodialysis three times per week each session for 4 hours patients with urea reduction ratio\>65% patients with transferrin saturation\>20% exclusion criteria: * patients with terminal illness or malignancy patients receiving hemodialysis from catheter or arteriovenous graft
bioequivalence of novoseven® and a novoseven® formulation stable at room temperature in healthy male subjects

Conditions: Acquired Bleeding Disorder; Acquired Haemophilia; Congenital Bleeding Disorder; Congenital FVII Deficiency; Glanzmann's Disease; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to demonstrate bio-equivalence between the marketed activated recombinant human factor vii (novoseven®) (cp-rfviia) and a new formulation stable at 25°c (vii25).


Eligibility criteria:
inclusion criteria: * caucasian * body mass index (bmi) between 18 and 27 kg/m\^2, both inclusive * good health as indicated by medical history, physical examination including vital signs and ecg, and clinical laboratory test results * smoke less than 10 cigarettes (or equivalent) per day * capable of giving written informed consent (ic) exclusion criteria: * evidence of clinically relevant pathology or potential thromboembolic risk based on medical and/or family history as judged by the investigator * known history of atherosclerosis, arteriosclerosis, thromboembolic events or known high levels of troponin i * known or suspected allergy to activated recombinant human factor vii or related products or any of the components of the formulation * overt bleeding, including from gastrointestinal tract * hepatitis (b or c) infection * hiv (human immunodeficiency virus) infection
preliminary review of cold and active compression therapy for traumatic calcaneus or ankle fractures

Conditions: Ankle Fractures

Summary: this study will examine the initial efficacy and cost-effectiveness of using the cryocompression therapy model both pre-operatively and post-operatively in patients that have recently suffered a traumatic calcaneus or ankle fracture compared to the standard pre-operative rice therapy procedures.

initial research has shown that cryocompression therapy applied post-operatively has been effective in reducing recovery time and improving health and pain factors related to patient recovery. however, there has been limited research into how this translates into positive economic outcomes for both the hospital and the patient. in addition, it can be reasonably hypothesized that the use of the cryocompression therapy system before surgery will lead to an increased rate of reduction in swelling necessary to allow proper operative procedures to take place when compared to the standard ice and elevation (rice) therapy techniques and cryocompression therapy applied only post-operatively. this should lead to decreased hospital costs and possible improved patient outcomes related to recovery. study objectives this study will examine the initial efficacy and cost-effectiveness of using the cryocompression therapy model both pre-operatively and post-operatively in patients that have recently suffered a traumatic calcaneus or ankle fracture compared to the standard pre-operative rice therapy procedures.

Eligibility criteria:
inclusion criteria: 1. patients over 18 years of age 2. able to provide informed consent 3. recent calcaneus or ankle fracture requiring fixation 4. injury is determined (by physician) to be an isolated, closed, low-energy bimalleolar fracture exclusion criteria: 1. unable to provide informed consent 2. history of dementia or mental instability 3. no recent additional fractures (within one year) at or around injury site 4. persons with symptoms of any kind of psychosocial disorder 5. any condition that the clinician feels would contraindicate for the postoperative test or control treatments 6. any conditions that would contraindicate using the game ready 7. if the patient is prevented from transfer to the or due to reasons other than medically necessary
midodrine and albumin in patients with refractory ascites

Conditions: Refractory Ascites

Summary: refractory ascites is seen in 5-10% of patients with cirrhosis.decompensated cirrhosis with refractory ascites has a mortality rate of around 40% in a year and a median survival of 6 months.portal hypertension and splanchnic vasodilation are major factors in the development of ascites.the treatment of refractory ascites involves salt restriction, diuretics, large volume paracentesis (lvp), transjugular intrahepatic portosystemic shunt (tips) and liver transplantation (lt). currently the only curative treatment is lt. however, lt is limited due to organ shortage and high cost. long-term human albumin (ha) administration in patients with uncomplicated and refractory ascites, has shown to improve survival or delay the complications of cirrhosis. midodrine, an oral α1- adrenergic agonist has been used in refractory ascites with variable results. however, there is no study on the use of long term midodrine and ha in patients with refractory ascites. therefore, we plan to study the effect of long term midodrine and ha in patients with refractory ascites.


Eligibility criteria:
inclusion criteria: 1. age between 18 and 80 years 2. refractory ascites in cirrhosis of any etiology exclusion criteria: 1. mixed ascites: cirrhosis plus another cause of ascites 2. gastrointestinal bleed within 7 days of enrolment. 3. presence of hepatorenal syndrome 4. hepatic encephalopathy grade 2 or higher 5. infection within 1 month preceding the study 6. cardiovascular disease (ejection fraction \ 140/90 mm of hg) 7. abnormal urine analysis with proteinuria \> 500 mg/24 hour or 50 red blood cells/high power field, or granular casts or ultrasonographic evidence of intrinsic renal disease 8. presence of hepatocellular carcinoma or portal vein thrombosis 9. treatment with drug with known effects on systemic and renal hemodynamics within 7 days of inclusion excepting beta-blockers 10. patient not willing for study. 11. patient opting for liver transplantation/ transjugular intrahepatic portosystemic shunt
effects of volatile anaesthetics on incidence of postoperative depression and anxiety in elderly patients

Conditions: Cohort Studies

Summary: this study is a retrospective analysis of a large-scale multicentre prospective cohort study that investigates the impact of volatile anaesthetics on the incidence of postoperative depression and anxiety among elderly patients.

studies have suggested volatile anaesthetics may alleviate depression and anxiety in patients. however, there is a paucity of research in this area. the investigatorswanted to determine the association between volatile anaesthetics and depression/anxiety in elderly patients within 7 days after surgery. this study retrospectively analysed data from a prospective database of patients aged 65 and above who underwent non-cardiac, non-neurosurgical elective surgery in 18 tertiary hospitals across 10 provinces in china. patients receiving volatile anaesthetics received at least one volatile anaesthetic (sevoflurane, isoflurane, desflurane), and those who received non-volatile anaesthetics did not receive any volatile anaesthetic. binary logistic regression analyses were conducted, and propensity score-matching (psm) and subgroup analyses were also applied.

Eligibility criteria:
inclusion criteria: geriatric surgical patients ≥65 years old non-selective cardiac surgery non-neurosurgical exclusion criteria: 1. underwent reoperation within 7 days 2. asa classification of ⅳ or above 3. history of serious mental illness or long-term use of psychotropic drugs 4. patients either died or were transferred to the intensive care unit within 7 days of the surgery 5. subjects with missing covariate data

Keywords: anxiety depression aged surgery volatile anaesthetics
giant cell tumor of the bone in young patients

Conditions: Giant Cell Tumor of Bone

Summary: single institution cases series review of histological and clinical data of young patient with giant cell tumors


Eligibility criteria:
inclusion criteria: 1. male and female patients under 15 years old treated at rizzoli institute from 01 january 1982 to 31 december 2018. 2. diagnosis of giant cell tumor of bone, aneurysmatic bone cysts with solid features and giant cell reparative granuloma. 3. histological slides/formalin-fixed paraffin-embedded tissue tumor blocks from archive available to perform the histology analysis 4. written informed consent prior to any study-specific analysis and/or data collection exclusion criteria: 1. patients with histological diagnosis different from diagnosis of giant cell tumor, aneurysmatic bone cysts with solid features, and giant cell reparative granuloma. 2. patients with no available material for additional immunohistochemical and molecular analysis